Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

Nicholas Nikesitch(Ingham Institute), Silvia Ling, M Wang(Westmead Institute for Medical Research), Tara L. Roberts(Camden and Campbelltown Hospitals), Sunna Bae(Ingham Institute), Murray C. Killingsworth(South Western Sydney Local Health District), Kaitao Lai(Liverpool Hospital), Simon J. Harrison(Peter MacCallum Cancer Centre)
Blood Cancer Journal
June 10, 2016
10.1038/bcj.2016.40
Cited by 28

Related Papers

HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
|The Lancet|2019|636
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
|Leukemia|2009|586
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507